Depomed is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. It offers Gralise (gabapentin), an once-daily product for the management of postherpetic neuralgia, and CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug indicated for acute treatment of migraine attacks in adults. Besides, the Company provides Zipsor (diclofenac potassium) liquid filled capsule, a non-steroidal anti-inflammatory drug for the treatment of mild to moderate acute pain in adults, and Lazanda (fentanyl) nasal spray, an intranasal fentanyl drug used to manage breakthrough pain in adults.

Type
Public
HQ
Newark, US
Founded
1995
Size (employees)
490 (est)
Depomed was founded in 1995 and is headquartered in Newark, US
Report incorrect company information

Key People/Management at Depomed

Arthur Higgins

Arthur Higgins

President and Chief Executive Officer
Matthew Gosling

Matthew Gosling

Senior Vice President and General Counsel
Mark Booth

Mark Booth

Senior Vice President, General Manager Specialty Business Unit
August Moretti

August Moretti

Chief Financial Officer and Senior Vice President

Depomed Office Locations

Depomed has an office in Newark
Newark, US (HQ)
300 7999 Gateway Blvd
Show all (1)
Report incorrect company information

Depomed Financials and Metrics

Depomed Financials

Depomed's revenue was reported to be $380.72 m in FY, 2017
USD

Revenue (FY, 2017)

380.7 m

Gross profit (FY, 2017)

308.1 m

Gross profit margin (FY, 2017), %

80.9%

Net income (FY, 2017)

(102.5 m)

EBIT (FY, 2017)

(42.2 m)

Market capitalization (20-Apr-2018)

420.2 m

Cash (31-Dec-2017)

126.9 m
Depomed's current market capitalization is $420.2 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

134.2 m390.4 m342.7 m455.9 m380.7 m

Revenue growth, %

191%(12%)33%

Cost of goods sold

7.1 m15.1 m67.9 m87.4 m72.6 m

Gross profit

127.1 m375.2 m274.8 m368.5 m308.1 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

76.5 m67.7 m51.5 m32.2 m94.5 m104.9 m104.8 m116.7 m110.5 m90.4 m100.5 m95.4 m

Cost of goods sold

3.7 m4.7 m3.5 m3.1 m22.9 m20.9 m23.5 m21 m20.2 m17.8 m19.7 m17.4 m

Gross profit

72.8 m63.1 m48 m29.1 m71.6 m83.9 m81.2 m95.7 m90.3 m72.7 m80.7 m78 m

Gross profit Margin, %

95%93%93%90%76%80%78%82%82%80%80%82%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

244.7 m488.7 m101.1 m117.7 m126.9 m

Accounts Receivable

11.5 m27 m71.1 m102.1 m71.9 m

Inventories

10.1 m8.5 m10.5 m13 m13 m

Current Assets

337 m617.6 m309 m306.2 m230.9 m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

195.3 m211.1 m546.7 m52.8 m94.1 m107.5 m182 m87.8 m90.4 m187.8 m113.2 m107.6 m

Accounts Receivable

12.8 m17.3 m20 m23.5 m59.8 m68.4 m69.9 m79.5 m87 m67.5 m78.3 m77.2 m

Inventories

8.5 m7.8 m7.3 m6.5 m10.4 m11.4 m10.9 m10.4 m11.3 m12 m10.4 m10.4 m

Current Assets

313.3 m309.6 m632.5 m613.5 m232.2 m302.8 m292.6 m230.2 m260.9 m286.8 m219 m219.3 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

43.3 m131.8 m(75.7 m)(88.7 m)(102.5 m)

Depreciation and Amortization

6.2 m12 m85.7 m106.8 m105.5 m

Inventories

4.3 m1.7 m9.3 m(3.7 m)(1.9 m)

Accounts Payable

16 m(2.7 m)(2.7 m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

17.9 m12.7 m6.5 m(11.6 m)(21.7 m)(11.8 m)(20.9 m)(10.5 m)(12.9 m)(26.7 m)(53.4 m)(16 m)

Depreciation and Amortization

2.5 m2.5 m2.5 m26.7 m27 m27 m27 m27 m26.3 m52.7 m

Inventories

7.8 m7.8 m7.3 m6.5 m10.4 m11.4 m10.9 m10.4 m11.3 m873 k490 k10.4 m

Accounts Payable

18.2 m3.2 m7.4 m11.3 m18.5 m(2.4 m)(2.7 m)7 m
USDY, 2017

Revenue/Employee

777 k

Financial Leverage

6.1 x
Show all financial metrics
Report incorrect company information

Depomed News and Updates

Pain Management Drugs & Devices Global Market 2018- Competitive Landscape, Strategies, Share, Trends, Segmentation, Growth Forecast 2022

This report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. Posted via Industry Today. Follow us on Twitter @IndustryToday

Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs

Depomed is selling off the franchise that was once the center of its growth hopes, and plenty of the company's employees are leaving with it. Less than three years after shelling out $1.05 billion to acquire Nucynta ER and XR from Johnson & Johnson, the California drugmaker has licensed the meds…
Report incorrect company information